What's Happening?
The U.S. Department of Health and Human Services (HHS) has released a policy brief arguing that the 340B drug discount program, originally designed to assist safety-net hospitals, now creates incentives for hospitals to overuse expensive drugs and expand
through consolidation. The analysis, conducted by economists within the department's Office of the Assistant Secretary for Planning and Evaluation, supports a proposed Medicare payment cut. The brief suggests that the program has expanded beyond its initial intent, leading hospitals to acquire drugs at discounted rates and then be reimbursed by Medicare at a standard rate, allowing them to retain the difference. This financial incentive, according to HHS, encourages the use of high-cost drugs and drives hospitals to add affiliated outpatient locations to also qualify for discounted drugs. The brief notes that hospital outpatient drug payments grew significantly from 2015-2017 and again from 2021-2023 after a previous Medicare payment cut was overturned.
Why It's Important?
This HHS analysis is significant because it directly informs a proposed rule by the Centers for Medicare and Medicaid Services (CMS) to reduce Medicare payments for 340B-acquired drugs. If finalized, this rule could lead to a substantial decrease in Medicare drug payments, estimated at $4.55 billion in the first year, and potentially lower out-of-pocket costs for Medicare enrollees by about $1.15 billion. However, hospital groups, including 340B Health and the American Hospital Association, strongly oppose the cut, arguing that 340B savings are crucial for funding care for low-income and uninsured patients. They warn that reduced funding could lead to cuts in essential safety-net services. Conversely, the Federation of American Hospitals, representing investor-owned hospitals, supports the proposed cut, and CMS estimates suggest that for-profit and rural sole community hospitals could benefit from the changes, while safety-net and major teaching hospitals might see payment reductions. The debate highlights a fundamental disagreement over the program's current impact and its role in healthcare financing.
What's Next?
A final rule from the Centers for Medicare and Medicaid Services (CMS) regarding the 2027 hospital outpatient payment is expected later this fall, with proposed changes set to take effect on January 1, 2027. This rule will determine whether Medicare will pay for 340B-acquired drugs at a reduced rate, specifically the average sales price minus 33.4%. The public comment period for this proposal has already closed. Additionally, a separate 340B rebate pilot program is scheduled to begin in January, which the American Hospital Association has already filed a lawsuit to block. Patients do not need to take immediate action, but Medicare enrollees with questions about drug coinsurance can consult their plan documents or hospital financial counselors. The final Medicare rule will reveal the extent to which the HHS analysis influences policy decisions and reshapes the financial landscape for hospitals and drug manufacturers participating in the 340B program.
Beyond the Headlines
The HHS analysis and the ensuing debate over the 340B program touch upon deeper issues within the U.S. healthcare system, particularly concerning drug pricing, hospital consolidation, and access to care for vulnerable populations. The argument that the program incentivizes the use of costlier drugs and drives consolidation raises questions about market efficiency and potential anti-competitive practices. The lack of transparency regarding how 340B savings are utilized by hospitals is a recurring concern, with members of Congress also seeking greater accountability. This situation underscores the complex interplay between federal programs, pharmaceutical companies, healthcare providers, and patient costs. The outcome of this policy debate could set a precedent for how government agencies evaluate and reform other healthcare programs, potentially leading to broader discussions about the balance between supporting safety-net providers and controlling overall healthcare expenditures. The ethical implications of financial incentives influencing medical decisions are also a key underlying theme.
